


Ellagic Acid Inhibitor of NDPK-B to Treat Cancer

Dr. Buxton and his colleagues observed that aggressive human tumors such as breast, lung, colon and prostate tumors, secrete nucleoside diphosphate kinase-B (NDPK-B). His studies furthermore showed that tumor-secreted NDPK-B is an important contributor to promoting angiogenesis and metastasis. Ellagic acid, which is recognized for its antiproliferative and antioxidant properties, is a powerful inhibitor of this enzyme.



Ellagic acid is a phytochemical, or plant chemical, found in raspberries, strawberries, cranberries, walnuts, pecans, pomegranates, and other plant foods.

Numerous in vitro and animal studies have suggested the antiproliferative and antioxidant properties of ellagic acid. Dr. Buxton's analysis demonstrates the mechanism of action of ellagic acid. It inhibits NDPK-B, an enzyme that produces elevated levels of extracellular ATP that plays a significant role in angiogenesis and metastasis.

*Intellectual
Property*

US patent 7,678,549

Claim 1: Methods of inhibiting tumor cell angiogenesis in a human tumor expressing and secreting nucleoside diphosphate kinase-B, comprising the steps of: a) identifying a human patient having a tumor, the cells of which express and secrete nucleoside diphosphate kinase-B; and b) contacting said cells of such a tumor with ellagic acid.

Available for exclusive or non-exclusive licensing

For more information, please contact our business development unit:

Dr. Alexandra Richardson +41-22-382-3802 or +41-76-342-7147 - arichardson@claytonbiotech